AR045462A1 - DERIVADOS DE INDOLES SUSTITUIDOS eTILES COMO COMPUESTOS FARMACEUTICOS PARA EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS - Google Patents
DERIVADOS DE INDOLES SUSTITUIDOS eTILES COMO COMPUESTOS FARMACEUTICOS PARA EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIASInfo
- Publication number
- AR045462A1 AR045462A1 ARP040102959A ARP040102959A AR045462A1 AR 045462 A1 AR045462 A1 AR 045462A1 AR P040102959 A ARP040102959 A AR P040102959A AR P040102959 A ARP040102959 A AR P040102959A AR 045462 A1 AR045462 A1 AR 045462A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- halogen
- aryl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado porque es de la fórmula (1), o una sal o solvato aceptables para uso farmacéutico del mismo, en donde: R1 es uno o más sustituyentes seleccionados entre hidrógeno, halógeno, CN, nitro, SO2R4, OH, OR4, S(O)xR4, SO2NR5R6, CONR5R6, NR5R6, NR9SO2R4, NR9SO2NR5R6, NR9CO2R4, NR9COR4, arilo, heteroarilo, C2-6 alquenilo, C2-6 alquinilo o C1-6 alquilo, donde los últimos cinco sustituyentes están opcionalmente sustituidos con uno o más sustituyentes seleccionados en forma independiente entre halógeno, CN, NR9SO2R4, NR9CO2R4, NR9COR4, OR8 y NR5R6, S(O)xR7 donde x es 0, 1 ó 2; R2 es hidrógeno, halógeno, CN, SO2R4 o CONR5R6, CH2OH, CH2OR4 o C1-7 alquilo, donde el último grupo están opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre átomos de halógeno, OR8, y NR5R6, S(O)xR7 donde es 0, 1 ó 2; R3 es arilo o heteroarilo donde cada uno de los cuales está opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre hidrógeno, halógeno, CN, nitro, OH, SO2R4,OR4, SR4, SOR4, SO2NR5R6, CONR5R6, NR5R6, NHSO2R4, NHCO2R4, NHCOR4, NR7SO2R4, NR7CO2R4, NR7COR4, NH(C1-6)alquilNR5R6, C2-6 alquenilo, C2-6 alquinilo, C1-6 alquilo, donde los últimos tres grupos están opcionalmente sustituidos con uno o más sustituyentes seleccionados en forma independiente entre átomos de halógeno, CN, OR8 y NR5R6, S(O)xR7 donde x es 0, 1 ó 2; R4 representa arilo, heteroarilo, o C1-6 alquilo donde todos pueden estar opcionalmente sustituidos con uno o más sustituyentes seleccionados en forma independiente entre átomos de halógeno, arilo, heteroarilo, OR10, OH, NR11R12, S(O)xR13 (donde x = 0, 1 ó 2), CONR14R15, NR14COR15, SO2NR14R15, NR14SO2R15, CN, nitro; R5 y R6 representan en forma independiente un átomo de hidrógeno, un grupo C1-6 alquilo, o un arilo, o un heteroarilo, donde los últimos tres pueden estar opcionalmente sustituidos con uno o más sustituyentes seleccionados en forma independiente entre átomos de halógeno, arilo, OR8 y R14R15, CONR14R15, NR14COR15, SO2NR14R15, NR14SO2R15, CN, nitro, o R5 y R6 junto con el átomo de nitrógeno al cual está unidos pueden formar un anillo heterocíclico saturado de entre 3 y 8 miembros que contiene opcionalmente uno o más átomos seleccionados entre O, S(O)x donde x = 0, 1 ó 2, NR16 y a su vez está opcionalmente sustituido con C1-3 alquilo; R7 y R13 representan en forma independiente un grupo C1-6 alquilo, arilo o heteroarilo, donde todos pueden estar opcionalmente sustituidos con átomos de halógeno; R8 representa un átomo de hidrógeno, C(O)R9, C1-6 alquilo (sustituido opcionalmente con átomos de halógeno o arilo) un grupo arilo o heteroarilo (sustituido opcionalmente con halógeno); cada uno de R9, R10, R11, R12, R14, R15, representa en forma independiente un átomo de hidrógeno, C1-6 alquilo, un grupo arilo o heteroarilo (donde todos pueden estar opcionalmente sustituidos con átomos de halógeno); y R16 es hidrógeno, C1-4 alquilo, -CO(C1-4 alquilo), COY(C1-4 alquilo) donde Y es O o NR7.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0302232A SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Novel Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR045462A1 true AR045462A1 (es) | 2005-10-26 |
Family
ID=28450248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040102959A AR045462A1 (es) | 2003-08-18 | 2004-08-18 | DERIVADOS DE INDOLES SUSTITUIDOS eTILES COMO COMPUESTOS FARMACEUTICOS PARA EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS |
Country Status (18)
Country | Link |
---|---|
US (1) | US7709521B2 (es) |
EP (1) | EP1656347B1 (es) |
JP (1) | JP4709758B2 (es) |
AR (1) | AR045462A1 (es) |
AT (1) | ATE484494T1 (es) |
CY (1) | CY1110977T1 (es) |
DE (1) | DE602004029580D1 (es) |
DK (1) | DK1656347T3 (es) |
ES (1) | ES2352201T3 (es) |
MY (1) | MY143367A (es) |
PL (1) | PL1656347T3 (es) |
PT (1) | PT1656347E (es) |
SA (1) | SA04250255B1 (es) |
SE (1) | SE0302232D0 (es) |
SI (1) | SI1656347T1 (es) |
TW (1) | TW200510303A (es) |
UY (1) | UY28473A1 (es) |
WO (1) | WO2005019171A1 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
SE0202241D0 (sv) * | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
SE0301569D0 (sv) * | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
SE0303180D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
NZ550365A (en) | 2004-03-11 | 2010-09-30 | Actelion Pharmaceuticals Ltd | Tetrahydropyridoindole derivatives |
PL1833791T3 (pl) | 2004-12-27 | 2011-12-30 | Actelion Pharmaceuticals Ltd | Pochodne 2,3,4,9-tetrahydro-1H-karbazolu jako antagonisty receptora CRTH2 |
GB0500604D0 (en) | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
GB0505048D0 (en) * | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
EP2397476A3 (en) | 2005-07-22 | 2011-12-28 | Shionogi & Co., Ltd. | Indole derivative having PGD2 receptor antagonist activity |
EP1911759A4 (en) | 2005-07-22 | 2010-07-21 | Shionogi & Co | AZAINDOL DERIVATIVE ANTAGONISTIC EFFECT ON PGD2 RECEPTOR |
GB0521275D0 (en) * | 2005-10-19 | 2005-11-30 | Argenta Discovery Ltd | 3-Aminoindole compounds |
CN102558021A (zh) * | 2006-05-26 | 2012-07-11 | 阿斯利康(瑞典)有限公司 | 联芳基或芳基-杂芳基取代的吲哚类化合物 |
DK2037967T3 (en) | 2006-06-16 | 2017-03-13 | Univ Pennsylvania | PROSTAGLANDIN-D2 RECEPTOR ANTAGONISTS FOR TREATMENT OF ANDROGENETIC ALOPECI |
US20150072963A1 (en) * | 2006-06-16 | 2015-03-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulating hair growth |
RU2458918C2 (ru) | 2006-07-22 | 2012-08-20 | Оксаген Лимитед | Соединения, обладающие антагонистической активностью по отношению к crth2 |
PL2051962T3 (pl) | 2006-08-07 | 2012-03-30 | Actelion Pharmaceuticals Ltd | Pochodne kwasu (3-amino-1,2,3,4-tetrahydro-9h-karbazol-9-ilo)-octowego |
EP2133332B1 (en) | 2007-04-11 | 2013-09-18 | Kissei Pharmaceutical Co., Ltd. | (aza)indole derivative and use thereof for medical purposes |
US7960567B2 (en) * | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
CA2707785C (en) | 2007-12-14 | 2015-11-03 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
EP2250161B1 (en) | 2008-01-18 | 2013-10-16 | Atopix Therapeutics Limited | Compounds having crth2 antagonist activity |
WO2009093029A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
US20100022613A1 (en) | 2008-01-22 | 2010-01-28 | Oxagen Limited | Compounds Having CRTH2 Antagonist Activity |
WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
AU2009331144A1 (en) * | 2008-12-25 | 2011-07-14 | Taisho Pharmaceutical Co., Ltd. | Isoquinoline derivative |
AR076590A1 (es) * | 2009-05-19 | 2011-06-22 | Vivia Biotech Sl | Metodos para proveer pruebas medicinales personalizada ex vivo para neoplasmas hematologicos |
WO2011004182A1 (en) * | 2009-07-06 | 2011-01-13 | Astrazeneca Ab | Intermediates and processes for the preparation of 4- (acetylamino) ) -3- [ (4-chloro-phenyl) thio] -2-methyl-1h-indole-1-acetic acid |
AU2011215638B2 (en) | 2010-02-11 | 2016-04-28 | Vanderbilt University | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mGluR4 allosteric potentiators, compounds, and methods of treating neurological dysfunction |
CN102791689B (zh) | 2010-03-22 | 2014-10-29 | 埃科特莱茵药品有限公司 | 3-(杂芳基-氨基)-1,2,3,4-四氢-9h-咔唑衍生物及其作为前列腺素d2受体调节剂的用途 |
SG186737A1 (en) | 2010-06-23 | 2013-02-28 | Taisho Pharmaceutical Co Ltd | Isoquinoline derivative |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
KR101928595B1 (ko) | 2011-04-14 | 2018-12-12 | 이도르시아 파마슈티컬스 리미티드 | 7-(헤테로아릴-아미노)-6,7,8,9-테트라히드로피리도[1,2-a]인돌 아세트산 유도체 및 프로스타글란딘 d2 수용체 조절자로서의 이의 용도 |
EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
EA026456B1 (ru) | 2011-12-16 | 2017-04-28 | Атопикс Терапьютикс Лимитед | Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита |
JP6193968B2 (ja) | 2012-03-21 | 2017-09-06 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 発毛を調節するための組成物および方法 |
HUE039614T2 (hu) | 2014-03-17 | 2019-01-28 | Idorsia Pharmaceuticals Ltd | Azaindol-ecetsav-származékok és prosztaglandin D2 receptor modulátorokként történõ alkalmazásuk |
ES2699379T3 (es) | 2014-03-18 | 2019-02-11 | Idorsia Pharmaceuticals Ltd | Derivados de ácido azaindol acético y su uso como moduladores del receptor de prostaglandina D2 |
GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
GB201407807D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
TWI695831B (zh) | 2014-09-13 | 2020-06-11 | 香港商南北兄弟藥業投資有限公司 | Crth2拮抗劑化合物及其用途 |
WO2017019858A1 (en) | 2015-07-30 | 2017-02-02 | The Trustees Of The University Of Pennsylvania | Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2 |
ES2867757T3 (es) | 2015-09-15 | 2021-10-20 | Idorsia Pharmaceuticals Ltd | Formas cristalinas |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
JPH0615542B2 (ja) | 1986-07-22 | 1994-03-02 | 吉富製薬株式会社 | ピラゾロピリジン化合物 |
US5095031A (en) * | 1990-08-20 | 1992-03-10 | Abbott Laboratories | Indole derivatives which inhibit leukotriene biosynthesis |
WO1993005020A1 (en) | 1991-09-06 | 1993-03-18 | Merck & Co., Inc. | Indoles as inhibitors of hiv reverse transcriptase |
FR2692574B1 (fr) | 1992-06-23 | 1995-06-23 | Sanofi Elf | Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles. |
AU6254294A (en) | 1993-02-24 | 1994-09-14 | Merck & Co., Inc. | Inhibitors of hiv reverse transcriptase |
US5486525A (en) | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
US5567711A (en) | 1995-04-19 | 1996-10-22 | Abbott Laboratories | Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists |
TW472045B (en) | 1996-09-25 | 2002-01-11 | Astra Ab | Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation |
WO1999009007A1 (en) | 1997-08-21 | 1999-02-25 | American Home Products Corporation | Solid phase synthesis of 2,3-disubstituted indole compounds |
DE69814012T2 (de) | 1997-12-19 | 2004-04-01 | Eli Lilly And Co., Indianapolis | Hypoglykàmische imidazoline derivate |
US6916841B2 (en) | 1998-02-25 | 2005-07-12 | Genetics Institute, Llc | Inhibitors of phospholipase enzymes |
WO2000078761A1 (en) | 1999-06-23 | 2000-12-28 | Sepracor, Inc. | Indolyl-benzimidazole antibacterials, and methods of use thereof |
WO2001032621A1 (fr) | 1999-10-29 | 2001-05-10 | Wakunaga Pharmaceutical Co., Ltd. | Nouveaux derives d'indole, et medicaments contenant lesdits derives comme principe actif |
EA005212B1 (ru) | 1999-12-24 | 2004-12-30 | Авентис Фарма Лимитед | Азаиндолы |
KR20030013433A (ko) * | 2000-05-31 | 2003-02-14 | 아스트라제네카 아베 | 혈관 손상 활성을 가진 인돌 유도체 |
US6878522B2 (en) * | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
TWI317634B (en) | 2001-12-13 | 2009-12-01 | Nat Health Research Institutes | Aroyl indoles compounds |
PL373410A1 (en) | 2002-02-01 | 2005-08-22 | F.Hoffman-La Roche Ag | Substituted indoles as alpha-1 agonists |
SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
US7534897B2 (en) | 2002-05-16 | 2009-05-19 | Shionogi & Co., Ltd. | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism |
TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0201635D0 (sv) * | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
SE0202241D0 (sv) * | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
SE0202463D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
SE0302232D0 (sv) | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
JP2007508363A (ja) | 2003-10-14 | 2007-04-05 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
GB0500604D0 (en) | 2005-01-13 | 2005-02-16 | Astrazeneca Ab | Novel process |
GB2422831A (en) | 2005-02-04 | 2006-08-09 | Oxagen Ltd | Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor |
CN102558021A (zh) | 2006-05-26 | 2012-07-11 | 阿斯利康(瑞典)有限公司 | 联芳基或芳基-杂芳基取代的吲哚类化合物 |
CA2654026A1 (en) | 2006-06-08 | 2007-12-13 | Neurokey A/S | Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia |
EP2040688B1 (en) | 2006-06-28 | 2014-04-02 | Sanofi | New cxcr2 inhibitors |
-
2003
- 2003-08-18 SE SE0302232A patent/SE0302232D0/xx unknown
-
2004
- 2004-08-06 TW TW093123728A patent/TW200510303A/zh unknown
- 2004-08-16 PT PT04768065T patent/PT1656347E/pt unknown
- 2004-08-16 SA SA04250255A patent/SA04250255B1/ar unknown
- 2004-08-16 DK DK04768065.7T patent/DK1656347T3/da active
- 2004-08-16 SI SI200431554T patent/SI1656347T1/sl unknown
- 2004-08-16 EP EP04768065A patent/EP1656347B1/en not_active Not-in-force
- 2004-08-16 JP JP2006523677A patent/JP4709758B2/ja not_active Expired - Fee Related
- 2004-08-16 WO PCT/GB2004/003502 patent/WO2005019171A1/en active Search and Examination
- 2004-08-16 PL PL04768065T patent/PL1656347T3/pl unknown
- 2004-08-16 AT AT04768065T patent/ATE484494T1/de active
- 2004-08-16 MY MYPI20043328A patent/MY143367A/en unknown
- 2004-08-16 US US10/568,889 patent/US7709521B2/en not_active Expired - Fee Related
- 2004-08-16 ES ES04768065T patent/ES2352201T3/es active Active
- 2004-08-16 DE DE602004029580T patent/DE602004029580D1/de active Active
- 2004-08-17 UY UY28473A patent/UY28473A1/es unknown
- 2004-08-18 AR ARP040102959A patent/AR045462A1/es not_active Application Discontinuation
-
2010
- 2010-12-09 CY CY20101101133T patent/CY1110977T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI1656347T1 (sl) | 2011-01-31 |
EP1656347B1 (en) | 2010-10-13 |
US7709521B2 (en) | 2010-05-04 |
SA04250255B1 (ar) | 2009-02-25 |
DK1656347T3 (da) | 2011-01-10 |
EP1656347A1 (en) | 2006-05-17 |
JP2007502804A (ja) | 2007-02-15 |
MY143367A (en) | 2011-04-29 |
CY1110977T1 (el) | 2015-06-11 |
UY28473A1 (es) | 2005-03-31 |
DE602004029580D1 (de) | 2010-11-25 |
WO2005019171A1 (en) | 2005-03-03 |
PT1656347E (pt) | 2010-12-09 |
PL1656347T3 (pl) | 2011-02-28 |
ES2352201T3 (es) | 2011-02-16 |
US20060264444A1 (en) | 2006-11-23 |
SE0302232D0 (sv) | 2003-08-18 |
TW200510303A (en) | 2005-03-16 |
JP4709758B2 (ja) | 2011-06-22 |
ATE484494T1 (de) | 2010-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR045462A1 (es) | DERIVADOS DE INDOLES SUSTITUIDOS eTILES COMO COMPUESTOS FARMACEUTICOS PARA EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS | |
AR044552A1 (es) | Derivados del indol,composiciones farmaceuticas que los contienen y procesos para su preparacion, de utilidad para el tratamiento de trastornos respiratorios | |
AR039934A1 (es) | Indoles sustituidos para el tratamiento de desordenes respiratorios | |
AR039933A1 (es) | Indoles sustituidos para tratamiento de desordenes respiratorios | |
AR040498A1 (es) | Indoles sustituidos utiles para el tratamiento de enfermedades respiratorias | |
CO5680430A2 (es) | Derivados de 1-benzol-piperazina como inhibidores de la captacion de glicina para el ratamiento de psicosis | |
AR079164A1 (es) | Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes. | |
AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
AR038814A1 (es) | Compuestos de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-ona y uso en la fabricacion de medicamentos | |
AR049399A1 (es) | Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos | |
AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
CY1106679T1 (el) | Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα | |
AR056892A1 (es) | Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa | |
CO5650164A2 (es) | Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
AR067845A1 (es) | Compuestos para tratar trastornos relacionados con la modulacion de receptores de rianodina y composicion farmaceutica | |
AR043998A1 (es) | Acidos fenoxiaceticos | |
AR049551A1 (es) | Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la beta-secretasa | |
AR045761A1 (es) | Derivados de 2-piridona como inhibidores de elastasa de neutrofilos | |
PE20130149A1 (es) | Derivados de la cromenona con actividad anti-tumoral | |
AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
PE20141075A1 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
CO5560575A2 (es) | Compuestos derivados de dihidro-pteridinonas caracterizados por ser inhibidores de especificas cinasas del ciclo celular y preparaciones farmaceuticas que los contienen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |